PortalPublikationenHospital-Level Variability in the Adoption of Image-Guided F...

Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer

Standard

Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer. / Qian, Zhiyu; Filipas, Dejan K.; Koelker, Mara; Stone, Benjamin V.; Beatrici, Edoardo; Labban, Muhieddine; Tuncali, Kemal; Lipsitz, Stuart; Trinh, Quoc-Dien; Cole, Alexander P.

in: CLIN GENITOURIN CANC, Jahrgang 22, Nr. 6, 102184, 12.2024.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Qian, Z, Filipas, DK, Koelker, M, Stone, BV, Beatrici, E, Labban, M, Tuncali, K, Lipsitz, S, Trinh, Q-D & Cole, AP 2024, 'Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer', CLIN GENITOURIN CANC, Jg. 22, Nr. 6, 102184. https://doi.org/10.1016/j.clgc.2024.102184

APA

Qian, Z., Filipas, D. K., Koelker, M., Stone, B. V., Beatrici, E., Labban, M., Tuncali, K., Lipsitz, S., Trinh, Q-D., & Cole, A. P. (2024). Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer. CLIN GENITOURIN CANC, 22(6), [102184]. https://doi.org/10.1016/j.clgc.2024.102184

Vancouver

Qian Z, Filipas DK, Koelker M, Stone BV, Beatrici E, Labban M et al. Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer. CLIN GENITOURIN CANC. 2024 Dez;22(6). 102184. https://doi.org/10.1016/j.clgc.2024.102184

Bibtex

@article{4a46c4afa4fc4a59b8e4906f376af973,
title = "Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer",
abstract = "BACKGROUND: Focal therapy, a minimally invasive procedure, offers targeted treatment for kidney and prostate cancer using image guidance. However, the current institutional landscape of its adoption in localized prostate and kidney cancer remains less understood. This analysis compares its usage between the 2 cancers to discern health system determinants affecting the adoption of these treatments.METHODS: The study used data from adult patients with localized prostate and kidney cancer from the National Cancer Database. We calculated adjusted probabilities of focal therapy usage per facility via multivariable mixed-effects logistic regression model with hospital-level random effects. We analyzed interhospital variability through ranked caterpillar plots and Spearman correlation coefficient.RESULTS: Among 1,559,334 prostate and 425,753 kidney cancer patients, 1.6% and 6.3% received focal therapy, respectively. The interhospital variation ranged from 0.13% to 32.17% for prostate cancer and 1.16% to 30.48% for kidney cancer. The hospital-level odds of focal therapy for prostate and kidney cancer were weakly correlated (Spearman's ρ = 0.21; P < .001).CONCLUSIONS: Our analysis revealed a substantial hospital-level discrepancy in the utilization of focal therapy. Despite this, there was a limited correlation between the use of focal therapy for these two types of cancer within the same hospital. Our findings emphasize the presence of multifaceted factors influencing the adoption of focal therapy, both at facility and healthcare system levels.",
keywords = "Prostate Cancer, Kidney Cancer, Focal Therapy, Focal Ablation, Health Services Research",
author = "Zhiyu Qian and Filipas, {Dejan K.} and Mara Koelker and Stone, {Benjamin V.} and Edoardo Beatrici and Muhieddine Labban and Kemal Tuncali and Stuart Lipsitz and Quoc-Dien Trinh and Cole, {Alexander P.}",
year = "2024",
month = dec,
doi = "10.1016/j.clgc.2024.102184",
language = "English",
volume = "22",
journal = "CLIN GENITOURIN CANC",
issn = "1558-7673",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer

AU - Qian, Zhiyu

AU - Filipas, Dejan K.

AU - Koelker, Mara

AU - Stone, Benjamin V.

AU - Beatrici, Edoardo

AU - Labban, Muhieddine

AU - Tuncali, Kemal

AU - Lipsitz, Stuart

AU - Trinh, Quoc-Dien

AU - Cole, Alexander P.

PY - 2024/12

Y1 - 2024/12

N2 - BACKGROUND: Focal therapy, a minimally invasive procedure, offers targeted treatment for kidney and prostate cancer using image guidance. However, the current institutional landscape of its adoption in localized prostate and kidney cancer remains less understood. This analysis compares its usage between the 2 cancers to discern health system determinants affecting the adoption of these treatments.METHODS: The study used data from adult patients with localized prostate and kidney cancer from the National Cancer Database. We calculated adjusted probabilities of focal therapy usage per facility via multivariable mixed-effects logistic regression model with hospital-level random effects. We analyzed interhospital variability through ranked caterpillar plots and Spearman correlation coefficient.RESULTS: Among 1,559,334 prostate and 425,753 kidney cancer patients, 1.6% and 6.3% received focal therapy, respectively. The interhospital variation ranged from 0.13% to 32.17% for prostate cancer and 1.16% to 30.48% for kidney cancer. The hospital-level odds of focal therapy for prostate and kidney cancer were weakly correlated (Spearman's ρ = 0.21; P < .001).CONCLUSIONS: Our analysis revealed a substantial hospital-level discrepancy in the utilization of focal therapy. Despite this, there was a limited correlation between the use of focal therapy for these two types of cancer within the same hospital. Our findings emphasize the presence of multifaceted factors influencing the adoption of focal therapy, both at facility and healthcare system levels.

AB - BACKGROUND: Focal therapy, a minimally invasive procedure, offers targeted treatment for kidney and prostate cancer using image guidance. However, the current institutional landscape of its adoption in localized prostate and kidney cancer remains less understood. This analysis compares its usage between the 2 cancers to discern health system determinants affecting the adoption of these treatments.METHODS: The study used data from adult patients with localized prostate and kidney cancer from the National Cancer Database. We calculated adjusted probabilities of focal therapy usage per facility via multivariable mixed-effects logistic regression model with hospital-level random effects. We analyzed interhospital variability through ranked caterpillar plots and Spearman correlation coefficient.RESULTS: Among 1,559,334 prostate and 425,753 kidney cancer patients, 1.6% and 6.3% received focal therapy, respectively. The interhospital variation ranged from 0.13% to 32.17% for prostate cancer and 1.16% to 30.48% for kidney cancer. The hospital-level odds of focal therapy for prostate and kidney cancer were weakly correlated (Spearman's ρ = 0.21; P < .001).CONCLUSIONS: Our analysis revealed a substantial hospital-level discrepancy in the utilization of focal therapy. Despite this, there was a limited correlation between the use of focal therapy for these two types of cancer within the same hospital. Our findings emphasize the presence of multifaceted factors influencing the adoption of focal therapy, both at facility and healthcare system levels.

KW - Prostate Cancer

KW - Kidney Cancer

KW - Focal Therapy

KW - Focal Ablation

KW - Health Services Research

U2 - 10.1016/j.clgc.2024.102184

DO - 10.1016/j.clgc.2024.102184

M3 - SCORING: Journal article

C2 - 39241314

VL - 22

JO - CLIN GENITOURIN CANC

JF - CLIN GENITOURIN CANC

SN - 1558-7673

IS - 6

M1 - 102184

ER -